Clarity Pharmaceuticals Ltd (CU6) - Total Liabilities

Latest as of June 2026: AU$12.96 Million AUD ≈ $9.17 Million USD

Based on the latest financial reports, Clarity Pharmaceuticals Ltd (CU6) has total liabilities worth AU$12.96 Million AUD (≈ $9.17 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore CU6 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.

Clarity Pharmaceuticals Ltd - Total Liabilities Trend (2018–2026)

This chart illustrates how Clarity Pharmaceuticals Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Clarity Pharmaceuticals Ltd balance sheet assets.

Clarity Pharmaceuticals Ltd Competitors by Total Liabilities

The table below lists competitors of Clarity Pharmaceuticals Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Atlanta Braves Holdings, Inc. Series A Common Stock NASDAQ:BATRA	USA	$1.21 Billion
Jiangsu Feymer Technology Co Ltd SHG:688350	China	CN¥1.24 Billion
Caisse Regionale de Credit Agricole Mutuel Brie Picardie PA:CRBP2	France	€35.94 Billion
Jiangsu Sihuan Bioengineering Co Ltd SHE:000518	China	CN¥123.67 Million
G-Tech Optoelectronics Corp TW:3149	Taiwan	NT$3.16 Billion
Insteel Industries Inc NYSE:IIIN	USA	$97.29 Million
Alpha Hpa Ltd AU:A4N	Australia	AU$88.65 Million
Zhejiang Tiancheng Control Co SHG:603085	China	CN¥2.57 Billion

Liability Composition Analysis (2018–2026)

This chart breaks down Clarity Pharmaceuticals Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Clarity Pharmaceuticals Ltd balance sheet independence to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	16.09	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.07	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.07	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Clarity Pharmaceuticals Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Clarity Pharmaceuticals Ltd (2018–2026)

The table below shows the annual total liabilities of Clarity Pharmaceuticals Ltd from 2018 to 2026.

Year	Total Liabilities	Change
2026-06-30	AU$12.96 Million ≈ $9.17 Million	+18.41%
2025-06-30	AU$10.94 Million ≈ $7.74 Million	+31.32%
2024-06-30	AU$8.33 Million ≈ $5.90 Million	+7.91%
2023-06-30	AU$7.72 Million ≈ $5.46 Million	+1.78%
2022-06-30	AU$7.59 Million ≈ $5.37 Million	+224.81%
2021-06-30	AU$2.34 Million ≈ $1.65 Million	+144.26%
2020-06-30	AU$956.09K ≈ $676.50K	-15.87%
2019-06-30	AU$1.14 Million ≈ $804.07K	+32.59%
2018-06-30	AU$857.04K ≈ $606.41K	--

About Clarity Pharmaceuticals Ltd

AU:CU6 Australia Biotechnology

Market Cap

$575.47 Million

AU$813.32 Million AUD

Market Cap Rank

#11631 Global

#297 in Australia

Share Price

AU$2.18

Change (1 day)

+3.81%

52-Week Range

AU$1.82 - AU$5.70

All Time High

AU$8.79